Proem Acquisition Corp I
PAACU · NASDAQ
About PAACU
- Employees
- 0
- Headquarters
- Dallas, Texas
- Listed
- Feb 12, 2026
- Sector
- N/A
- Industry
- N/A
PAACU key statistics
- Market cap
- 177.41M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 48
- Volume
- 2.07K
- Open price
- $10.30
- High today
- $10.30
- Low today
- $10.30
- 52 Week high
- $10.50
- 52 Week low
- $9.95
Proem Acquisition Corp I (PAACU) at a glance
As of Nov 2, 2026, Proem Acquisition Corp I (PAACU) shares are priced at $10.30, giving the company a market cap of 177.41M and a price-to-earnings ratio of 0.00.
Volume so far is 2.07K shares, above the average of 48 shares a day.
Over the past year Proem Acquisition Corp I has ranged from $9.95 to $10.50, and now sits 64% of the way up that range.
Most active stocks
Highest trading volume today
- INLFINLIF$0.2899+56.70%
- RBNERobin Energy$0.151+8.95%
- GMZPGemz$0.0001−50.00%
- INTCIntel$59.97−8.80%
- INOInovio Pharmaceuticals$1.90+215.31%
- XXII22nd Century Group$0.0741+6.47%
- NVDGraniteShares ETF Trust$4.54+2.60%
- TMGITransglobal Management Group$0.0001−33.33%
- BDMDBaird Medical Investment Holdings$0.138−13.97%
- SOXLDirexion Shares ETF Trust$68.17−11.52%
- RDARRaadr$0.0002+0.00%
- EARIEntertainment Arts Research$0.0002+0.00%
Newly listed
Companies that went public in the past six weeks
- GBCGEORGIA BANKING$37.28−2.87%
- BHAIUBHAV Acquisition Corp II$10.00+0.15%
- SCQCUSPACCircle Acquisition$9.97−0.15%
- LYCALycia Therapeutics$27.18+2.95%
- DAVIDAVION HEALTHCARE$1.49−11.31%
- TCXBTCGX Acquisition Corp. II$10.10−0.39%
- CTYCITY THERAPEUTICS$20.88+0.82%
- IAMIambic Therapeutics$12.96−3.54%
- AMROAmaero$5.72+2.88%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.16−0.10%
- TRXBTRex Bio$13.64−0.73%
- RTSNRetension Pharmaceuticals$11.30−0.53%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.